Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy

Por Johnson, Burles A, Baban, Babak, Mellor, Andrew L
Publicado em 2009

Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilege

Por Huang, Lei, Baban, Babak, Johnson, Burles A, Mellor, Andrew L.
Publicado em 2010

B-lymphoid cells with attributes of dendritic cells regulate T cells via indoleamine 2,3-dioxygenase

Por Johnson, Burles A., Kahler, David J., Baban, Babak, Chandler, Phillip R., Kang, Baolin, Shimoda, Michiko, Koni, Pandelakis A., Pihkala, Jeanene, Vilagos, Bojan, Busslinger, Meinrad, Munn, David H., Mellor, Andrew L.
Publicado em 2010

Physiologic control of IDO-competence in splenic dendritic cells

Por Baban, Babak, Chandler, Phillip R., Johnson, Burles A., Huang, Lei, Li, Minghui, Sharpe, Marlon L., Francisco, Loise M., Sharpe, Arlene H., Blazar, Bruce R., Munn, David H., Mellor, Andrew L.
Publicado em 2011

Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase

Por Muller, Alexander J., Sharma, Madhav D., Chandler, Phillip R., DuHadaway, James B., Everhart, Mary E., Johnson, Burles A., Kahler, David J., Pihkala, Jeanene, Soler, Alejandro Peralta, Munn, David H., Prendergast, George C., Mellor, Andrew L.
Publicado em 2008